MEI Pharma outlicenses PI3K inhibitor to Kyowa in Japan, BeiGene in China

MEI Pharma Inc. (NASDAQ:MEIP) granted Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) exclusive rights in Japan to develop and commercialize ME-401, initially for relapsed or refractory follicular lymphoma. ME-401 is a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor. Kyowa plans to begin a Phase I study of the compound in Japan next year.

MEI will receive $10 million up front and is eligible for up to $87.5 million in milestones. ...